Pharma Journalist -

Arrowhead Pharmaceuticals has secured a major regulatory milestone with the U.S. Food and Drug Administration’s approval of REDEMPLO (plozasiran), marking the company’s first…
Read More...

The European Commission has approved Merck’s new subcutaneous formulation of Keytruda, branded as KEYTRUDA SC, making it the first subcutaneous immune checkpoint inhibitor available in…
Read More...

April 6-8, 2026 | Boston, MA – Against a backdrop of major industry acquisitions including AbbVie/Capstan Therapeutics, Eli Lilly & Co/Verve Therapeutics, and now BMS/Orbital…
Read More...

The European Commission has approved Insmed’s BRINSUPRI (brensocatib 25 mg tablets) as the first and only authorized treatment for non-cystic fibrosis bronchiectasis (NCFB) in the…
Read More...

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s EPKINLY® (epcoritamab-bysp), a subcutaneously administered T-cell engaging bispecific antibody, in combination with…
Read More...

Genprex, Inc. has strengthened the intellectual property protection surrounding its lead drug candidate, REQORSA® Gene Therapy, with the announcement that the U.S. Patent and Trademark…
Read More...

Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company developing next-generation targeted cancer…
Read More...

Biogen announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a unanimous positive opinion recommending approval of a high-dose…
Read More...

Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotech developing oral, targeted cancer therapies using its proprietary…
Read More...

Merus N.V. and Halozyme Therapeutics have entered into a global, non-exclusive collaboration and license agreement to develop and potentially commercialize a subcutaneous formulation of…
Read More...